CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus-Reference-Cited by-同舟云学术

CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus

Published:2019-08 Issue:13 Volume:20 Page:939-946
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Rooney Sydney R¹,Shelton Elaine L²,Aka Ida²,Shaffer Christian M³,Clyman Ronald I⁴,Dagle John M⁵,Ryckman Kelli⁶,Lewis Tamorah R⁷,Reese Jeff²,Van Driest Sara L²³,Kannankeril Prince J²

Affiliation:

1. Vanderbilt University School of Medicine, UCSF, Nashville, TN 37232, USA

2. Department of Pediatrics, Vanderbilt University Medical Center, UCSF, Nashville, TN 37232, USA

3. Department of Medicine, Vanderbilt University Medical Center, UCSF, Nashville, TN 37232, USA

4. Department of Pediatrics & Cardiovascular Research Center, University of California San Francisco, San Francisco, CA 94143, USA

5. Department of Pediatrics, University of Iowa, Iowa City, UMKC, IA 52242, USA

6. Department of Epidemiology, University of Iowa, Iowa City, UMKC, IA 52242, USA

7. Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, MO 64110, USA

Abstract

Aims: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). Patients & Methods: This is a multicenter cohort study of 144 preterm infants (22–32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. Results: In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60–0.96), surfactant use (AOR 9.77, 95% CI 1.15–83.26), and CYP2C9*2 (AOR 3.74; 95% CI 1.34–10.44) were each associated with indomethacin failure. Conclusion: Age, surfactant use, and CYP2C9*2 influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2019-0079

Reference32 articles.

1. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3

2. Patent ductus arteriosus, its treatments, and the risks of pulmonary morbidity

3. Covariation of Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Management and In-Neonatal Intensive Care Unit Outcomes Following Preterm Birth

4. Clinical Pharmacology of Indomethacin in Preterm Infants: Implications in Patent Ductus Arteriosus Closure

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between endotypes of prematurity and pharmacological closure of patent ductus arteriosus: A systematic review and meta-analysis;Frontiers in Pediatrics;2023-03-03

2. Precision Medicine in Pediatric Cardiology;Pediatric Annals;2022-10

3. Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider;Journal of the American Heart Association;2022-09-06

4. Fetal pharmacogenetic screening to improve neonatal pharmacotherapy: From feasibility to personalized practice;Molecular Genetics and Metabolism;2022-09

5. Integrated in a systems pharmacology approach, pharmacogenetics holds the promise for personalized medicine in neonates;Pharmacogenomics;2022-08